Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Characterization of immune checkpoint inhibitor‐induced cardiotoxicity reveals interleukin‐17A as a driver of cardiac dysfunction after anti‐PD‐1 treatment
Tamás G. Gergely, Dániel Kucsera, Viktória É. Tóth, et al.
British Journal of Pharmacology (2022) Vol. 180, Iss. 6, pp. 740-761
Open Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence
Nabil V. Sayour, Á. Paál, Pietro Ameri, et al.
European Heart Journal (2024) Vol. 45, Iss. 14, pp. 1224-1240
Open Access | Times Cited: 18
Immune checkpoints in cardiac physiology and pathology: therapeutic targets for heart failure
Tamás G. Gergely, Zsófia D. Drobni, Marinos Kallikourdis, et al.
Nature Reviews Cardiology (2024) Vol. 21, Iss. 7, pp. 443-462
Closed Access | Times Cited: 15
Early microvascular coronary endothelial dysfunction precedes pembrolizumab-induced cardiotoxicity. Preventive role of high dose of atorvastatin
Panagiotis Efentakis, Angeliki Choustoulaki, Grzegorz Kwiatkowski, et al.
Basic Research in Cardiology (2024)
Open Access | Times Cited: 13
Molecular fingerprints of cardiovascular toxicities of immune checkpoint inhibitors
Tamás G. Gergely, Zsófia D. Drobni, Nabil V. Sayour, et al.
Basic Research in Cardiology (2024)
Open Access | Times Cited: 8
Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians
Emanuel Raschi, Simone Rossi, Andrea De Giglio, et al.
Drug Safety (2023) Vol. 46, Iss. 9, pp. 819-833
Open Access | Times Cited: 18
Combinatorial immune checkpoint blockade increases myocardial expression of NLRP-3 and secretion of H-FABP, NT-Pro-BNP, interleukin-1β and interleukin-6: biochemical implications in cardio-immuno-oncology
Vincenzo Quagliariello, Margherita Passariello, Isabella Bisceglia, et al.
Frontiers in Cardiovascular Medicine (2024) Vol. 11
Open Access | Times Cited: 5
IL‐17 is associated with disease severity and targetable inflammatory processes in heart failure
Lukas Baumhove, Bart J van Essen, Martin M. Dokter, et al.
ESC Heart Failure (2024) Vol. 11, Iss. 6, pp. 3530-3538
Open Access | Times Cited: 5
Targeting the NLRP3 inflammasome abrogates cardiotoxicity of immune checkpoint blockers
Lu Yang, Jiamin Gao, Yachen Hou, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 1, pp. e010127-e010127
Open Access
Subepicardial adipose genes contribute to the deterioration of heart failure preserved ejection fraction
Ruiying Zhang, Man Wang, Yuheng Lang, et al.
Frontiers in Cardiovascular Medicine (2025) Vol. 12
Open Access
Cardiovascular Risk Profile of Nivolumab Anti-cancer Therapy
Zaheer Qureshi, Zaofashan Zaheer, Zoha Asghar, et al.
American Journal of Clinical Oncology (2025)
Closed Access
Immune checkpoint inhibitor-associated myocarditis: a review of current state of knowledge
Keila C. Ostos-Mendoza, Valeria Saraiba-Rabanales, Paola Gutierrez-Gallegos, et al.
The Journal of Cardiovascular Aging (2025) Vol. 5, Iss. 1
Open Access
Diagnostic value of ROCK2 protein in immune checkpoint inhibitors-associated myocarditis
Caie Li, Yucheng Jin, Ma J, et al.
International Journal of Cardiology (2025) Vol. 427, pp. 133104-133104
Closed Access
Oridonin Alleviates Doxorubicin‐Induced Cardiotoxicity by Inhibiting p38 MAPK/MMP3 Signaling Pathway
Xingyuan Hou, Suifen Xie, Ni Zhou, et al.
Chemical Biology & Drug Design (2025) Vol. 105, Iss. 3
Closed Access
Predicting 30-Day Cardiotoxicity in Patients Receiving Immune Checkpoint Inhibitors: An Observational Study Utilizing XGBoost
J. Li, Z.-G. Chen, Yuxi Zhu, et al.
Cardiovascular Toxicology (2025)
Closed Access
Mechanisms of Cardiovascular Toxicities Induced by Cancer Therapies and Promising Biomarkers for Their Prediction: A Scoping Review
Tingting Yan, Hailong Yu, Tai Li, et al.
Heart Lung and Circulation (2024) Vol. 33, Iss. 5, pp. 605-638
Closed Access | Times Cited: 4
Preclinical models of cardiotoxicity from immune checkpoint inhibitor therapy
Florian Buehning, Tobias Lerchner, Julia K. Vogel, et al.
Basic Research in Cardiology (2024)
Open Access | Times Cited: 4
Diagnostic Value of Rock2 Protein in Immune Checkpoint Inhibitors-Associated Myocarditis
Caie Li, Yucheng Jin, Ma J, et al.
(2025)
Closed Access
From Bench to Bedside: Translational Approaches to Cardiotoxicity in Breast Cancer, Lung Cancer, and Lymphoma Therapies
Valerio Nardone, Dafne Ruggiero, Maria Giovanna Chini, et al.
Cancers (2025) Vol. 17, Iss. 7, pp. 1059-1059
Open Access
Antineoplastic drugs inducing cardiac and vascular toxicity – An update
Serena Barachini, Sandra Ghelardoni, Zoltán V. Varga, et al.
Vascular Pharmacology (2023) Vol. 153, pp. 107223-107223
Closed Access | Times Cited: 10
Cellular Alterations in Immune Checkpoint Inhibitor Therapy-Related Cardiac Dysfunction
Lars Michel, Péter Ferdinandy, Tienush Rassaf
Current Heart Failure Reports (2024) Vol. 21, Iss. 3, pp. 214-223
Open Access | Times Cited: 3
Inhibition of IL-25/IL-17RA improves immune-related adverse events of checkpoint inhibitors and reveals antitumor activity
X Hu, Shoiab Bukhari, Carly Tymm, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 3, pp. e008482-e008482
Open Access | Times Cited: 3
Implications and hidden toxicity of cardiometabolic syndrome and early‐stage heart failure in carfilzomib‐induced cardiotoxicity
Panagiotis Efentakis, Aimilia Varela, Sofia Lamprou, et al.
British Journal of Pharmacology (2024) Vol. 181, Iss. 16, pp. 2964-2990
Open Access | Times Cited: 3
Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, et al.
British Journal of Pharmacology (2024)
Open Access | Times Cited: 3
Protective effect of low‐intensity pulsed ultrasound on immune checkpoint inhibitor-related myocarditis via fine-tuning CD4+ T-cell differentiation
Shuai Fu, Zihong Guo, Xiangli Xu, et al.
Cancer Immunology Immunotherapy (2024) Vol. 73, Iss. 1
Open Access | Times Cited: 2
Immunotherapy-associated cardiovascular toxicities: insights from preclinical and clinical studies
Youqian Kong, Xiaoyu Wang, Rui Qie
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top